LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 28

Search options

  1. Article ; Online: Difelikefalin suppresses itch and reduces scratching independent of inflammation in a murine model of atopic dermatitis.

    Tamari, Masato / Zamidar, Lydia / Ver Heul, Aaron M / Nograles, Kristine / Goncalves, Joana / Guttman-Yassky, Emma / Lebwohl, Mark / Kim, Brian S

    The Journal of allergy and clinical immunology

    2023  Volume 152, Issue 4, Page(s) 927–932

    Abstract: Background: Therapies specifically targeting nonhistaminergic pruritus are largely lacking. Difelikefalin (DFK) has been found to reduce itch in various chronic pruritic conditions, including atopic dermatitis (AD).: Objective: We sought to ... ...

    Abstract Background: Therapies specifically targeting nonhistaminergic pruritus are largely lacking. Difelikefalin (DFK) has been found to reduce itch in various chronic pruritic conditions, including atopic dermatitis (AD).
    Objective: We sought to investigate the ability of DFK to impact scratching behavior, inflammatory mediators, and neuronal signaling in a murine model of AD.
    Methods: The ears of C57BL/6 mice were topically treated with MC903 for 12 consecutive days to induce AD-like inflammation and itch. Before MC903 treatment, mice were treated with either DFK (0.5 mg/kg, intraperitoneal injection twice daily) or vehicle (saline). Skin ear thickness, histological analysis, flow cytometry, RNA-sequencing, and differential gene expression analyses of mouse ear skin were used to examine the effect of DFK on skin inflammation. Scratching behavior was quantified to measure itch behavior in mice that were topically treated with MC903 for 6 consecutive days; then, mice received a single injection of either DFK (1.0 mg/kg, intraperitoneal injection) or saline. Calcium imaging and single-cell RNA-sequencing were used in mouse dorsal root ganglia neurons to determine the size of the neurons activated with DFK treatment. Statistical significance was determined by Mann-Whitney test, unless otherwise noted.
    Results: DFK rapidly suppressed itch without altering AD-like skin inflammation in MC903 (calcipotriol)-treated mice. In vitro Ca
    Conclusions: These studies support a potential neuromodulatory role of DFK for reducing itch associated with AD in mice.
    MeSH term(s) Mice ; Animals ; Dermatitis, Atopic/pathology ; Disease Models, Animal ; Mice, Inbred C57BL ; Pruritus/pathology ; Skin/pathology ; Inflammation/drug therapy ; Inflammation/metabolism ; RNA/metabolism
    Chemical Substances difelikefalin (NA1U919MRO) ; RNA (63231-63-0)
    Language English
    Publishing date 2023-07-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 121011-7
    ISSN 1097-6825 ; 1085-8725 ; 0091-6749
    ISSN (online) 1097-6825 ; 1085-8725
    ISSN 0091-6749
    DOI 10.1016/j.jaci.2023.06.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Anti-cytokine therapies for psoriasis.

    Nograles, Kristine E / Krueger, James G

    Experimental cell research

    2011  Volume 317, Issue 9, Page(s) 1293–1300

    Abstract: Current approaches for the treatment of psoriasis with anti-cytokine therapies involve the blockade of TNF-α, or the p40 sub-unit of IL-12 and IL-23. However, the field is currently evolving to test more selective antagonists, such as anti-IL-23p19, IL- ... ...

    Abstract Current approaches for the treatment of psoriasis with anti-cytokine therapies involve the blockade of TNF-α, or the p40 sub-unit of IL-12 and IL-23. However, the field is currently evolving to test more selective antagonists, such as anti-IL-23p19, IL-17 and other inflammatory cytokines. Here we discuss our current understanding of dendritic cell and T cell subsets that are relevant in psoriasis, and the pharmacologic strategies that temper their activity in this disease.
    MeSH term(s) Animals ; Antibodies/therapeutic use ; Cytokines/immunology ; Humans ; Protein Subunits/immunology ; Psoriasis/drug therapy ; Psoriasis/immunology ; T-Lymphocytes/immunology
    Chemical Substances Antibodies ; Cytokines ; Protein Subunits
    Language English
    Publishing date 2011-05-15
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1493-x
    ISSN 1090-2422 ; 0014-4827
    ISSN (online) 1090-2422
    ISSN 0014-4827
    DOI 10.1016/j.yexcr.2011.01.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient Survey.

    Silverberg, Jonathan I / Mohawk, Jennifer A / Cirulli, Joshua / Nograles, Kristine / Punzalan, Joseph C / Kelly, Kevin M / Kim, Brian S / Guttman-Yassky, Emma / Lebwohl, Mark

    Dermatitis : contact, atopic, occupational, drug

    2023  Volume 34, Issue 2, Page(s) 135–144

    Abstract: Background: ...

    Abstract Background:
    MeSH term(s) Adult ; Humans ; Dermatitis, Atopic/drug therapy ; Dermatitis, Atopic/epidemiology ; Severity of Illness Index ; Pruritus/etiology ; Pruritus/therapy ; Pruritus/diagnosis ; Surveys and Questionnaires ; Cost of Illness ; Quality of Life
    Language English
    Publishing date 2023-01-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2144723-8
    ISSN 2162-5220 ; 1532-8163 ; 1710-3568
    ISSN (online) 2162-5220 ; 1532-8163
    ISSN 1710-3568
    DOI 10.1089/derm.2022.29015.jsi
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis.

    Guttman-Yassky, Emma / Facheris, Paola / Da Rosa, Joel Correa / Rothenberg-Lausell, Camille / Del Duca, Ester / David, Eden / Estrada, Yeriel / Liu, Ying / Bose, Swaroop / Chowdhury, Mashkura / Munera, Catherine / Goncalves, Joana / Nograles, Kristine / Kim, Brian S / Lebwohl, Mark

    The Journal of allergy and clinical immunology

    2023  Volume 152, Issue 4, Page(s) 916–926

    Abstract: Background: Pruritus is the most common and burdensome symptom of atopic dermatitis (AD). Pruritus-targeted treatments in AD are lacking, particularly for patients with milder skin disease.: Objective: We sought to evaluate the impact of the ... ...

    Abstract Background: Pruritus is the most common and burdensome symptom of atopic dermatitis (AD). Pruritus-targeted treatments in AD are lacking, particularly for patients with milder skin disease.
    Objective: We sought to evaluate the impact of the selective κ-opioid receptor agonist difelikefalin (DFK) on pruritus intensity and pruritus- and immune-related biomarkers in subjects with moderate to severe AD-related pruritus.
    Methods: A phase 2 clinical trial investigated the efficacy and safety of oral DFK 0.25, 0.5, and 1.0 mg in subjects with moderate to severe AD-related pruritus. A biomarker substudy evaluated the effects of DFK on the expression of pruritus, T
    Results: In the clinical trial (N = 401), all DFK doses reduced itch versus placebo; however, the results were not statistically significant at week 12. In a subgroup of subjects in the trial with mild to moderate skin inflammation and moderate to severe itch (itch-dominant AD phenotype), DFK reduced itch at week 12 versus placebo. In the biomarker substudy, DFK downregulated the expression of key pruritus-related genes (eg, IL-31 and TRPV1) and the AD phenotype (eg, CCL17). Gene set variation analysis confirmed that DFK, but not placebo, downregulated pruritus-related genes and T
    Conclusions: DFK treatment reduced itch in subjects with moderate to severe AD-related pruritus, particularly those with an "itch-dominant" AD phenotype, and had an impact on the expression of pruritus, T
    MeSH term(s) Humans ; Dermatitis, Atopic/drug therapy ; Dermatitis, Atopic/metabolism ; Pruritus/drug therapy ; Pruritus/metabolism ; Skin/metabolism ; Biomarkers/metabolism ; Severity of Illness Index
    Chemical Substances difelikefalin (NA1U919MRO) ; Biomarkers
    Language English
    Publishing date 2023-07-13
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 121011-7
    ISSN 1097-6825 ; 1085-8725 ; 0091-6749
    ISSN (online) 1097-6825 ; 1085-8725
    ISSN 0091-6749
    DOI 10.1016/j.jaci.2023.06.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts.

    Guttman-Yassky, Emma / Nograles, Kristine E / Krueger, James G

    The Journal of allergy and clinical immunology

    2011  Volume 127, Issue 5, Page(s) 1110–1118

    Abstract: Atopic dermatitis and psoriasis are 2 of the most common inflammatory skin diseases. They are similar in that they are complex inherited diseases involving genes that encode immune components and structural proteins that regulate differentiation of ... ...

    Abstract Atopic dermatitis and psoriasis are 2 of the most common inflammatory skin diseases. They are similar in that they are complex inherited diseases involving genes that encode immune components and structural proteins that regulate differentiation of epidermal cells. Each disease is characterized by proliferation of epidermal keratinocytes and abnormal cornification or terminal differentiation in the epidermis; skin lesions contain immune infiltrates of T cells, dendritic cells, and other types of leukocytes. We review similarities between the diseases and differences in epidermal barrier defects and immune cells. We also propose mechanisms of pathogenesis based on differences in the balance of immune cell subsets that could cause the phenotypes that distinguish these diseases. The first part of this 2-part review focuses on the clinical and pathologic features of the diseases; the second part discusses differences in immune cell subsets between atopic dermatitis and psoriasis and recent therapeutic strategies.
    MeSH term(s) Adult ; Animals ; Child ; Dermatitis, Atopic/genetics ; Dermatitis, Atopic/immunology ; Dermatitis, Atopic/pathology ; Dermatitis, Atopic/physiopathology ; Humans ; Mice ; Psoriasis/genetics ; Psoriasis/immunology ; Psoriasis/pathology ; Psoriasis/physiopathology
    Language English
    Publishing date 2011-05
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 121011-7
    ISSN 1097-6825 ; 1085-8725 ; 0091-6749
    ISSN (online) 1097-6825 ; 1085-8725
    ISSN 0091-6749
    DOI 10.1016/j.jaci.2011.01.053
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts.

    Guttman-Yassky, Emma / Nograles, Kristine E / Krueger, James G

    The Journal of allergy and clinical immunology

    2011  Volume 127, Issue 6, Page(s) 1420–1432

    Abstract: Atopic dermatitis (AD) and psoriasis are among the most common inflammatory skin diseases. In the first part of this 2-part review, we discussed the similarities and differences between AD and psoriasis with respect to clinical features and pathology. ... ...

    Abstract Atopic dermatitis (AD) and psoriasis are among the most common inflammatory skin diseases. In the first part of this 2-part review, we discussed the similarities and differences between AD and psoriasis with respect to clinical features and pathology. The diseases are characterized by infiltration of skin lesions by large numbers of inflammatory cells; the second part of this review focuses on immune cell subsets that distinguish each disease and the therapeutic strategies that might be used or developed based on this information. We discuss the interactions among different populations of immune cells that ultimately create the complex inflammatory phenotype of AD and compare these with psoriasis. Therapeutic strategies have been developed for psoriasis based on the cytokine network that promotes inflammation in this disease. Antibodies against IL-12 and IL-23p40 antibody and antagonists of TNF are used to treat patients with psoriasis, and studies are underway to test specific antagonists of IL-23, IL-17, IL-17 receptor, IL-20, and IL-22. We discuss how these therapeutic approaches might be applied to AD.
    MeSH term(s) Adaptive Immunity ; Cytokines/metabolism ; Dendritic Cells/immunology ; Dermatitis, Atopic/etiology ; Dermatitis, Atopic/immunology ; Dermatitis, Atopic/therapy ; Eosinophils/immunology ; Humans ; Immunity, Innate ; Immunosuppressive Agents/therapeutic use ; Inflammation Mediators/metabolism ; Keratinocytes/immunology ; Mast Cells/immunology ; Models, Biological ; Psoriasis/etiology ; Psoriasis/immunology ; Psoriasis/therapy ; T-Lymphocyte Subsets/immunology
    Chemical Substances Cytokines ; Immunosuppressive Agents ; Inflammation Mediators
    Language English
    Publishing date 2011-06
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Review
    ZDB-ID 121011-7
    ISSN 1097-6825 ; 1085-8725 ; 0091-6749
    ISSN (online) 1097-6825 ; 1085-8725
    ISSN 0091-6749
    DOI 10.1016/j.jaci.2011.01.054
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Anti-cytokine therapies for psoriasis

    Nograles, Kristine E / Krueger, James G

    Experimental cell research. 2011 May 15, v. 317, no. 9

    2011  

    Abstract: Current approaches for the treatment of psoriasis with anti-cytokine therapies involve the blockade of TNF-α, or the p40 sub-unit of IL-12 and IL-23. However, the field is currently evolving to test more selective antagonists, such as anti-IL-23p19, IL- ... ...

    Abstract Current approaches for the treatment of psoriasis with anti-cytokine therapies involve the blockade of TNF-α, or the p40 sub-unit of IL-12 and IL-23. However, the field is currently evolving to test more selective antagonists, such as anti-IL-23p19, IL-17 and other inflammatory cytokines. Here we discuss our current understanding of dendritic cell and T cell subsets that are relevant in psoriasis, and the pharmacologic strategies that temper their activity in this disease.
    Keywords T-lymphocytes ; antagonists ; interleukin-12 ; interleukin-17 ; interleukin-23 ; psoriasis ; tumor necrosis factor-alpha
    Language English
    Dates of publication 2011-0515
    Size p. 1293-1300.
    Publishing place Elsevier Inc.
    Document type Article
    ZDB-ID 1493-x
    ISSN 1090-2422 ; 0014-4827
    ISSN (online) 1090-2422
    ISSN 0014-4827
    DOI 10.1016/j.yexcr.2011.01.024
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  8. Article ; Online: New insights in the immunologic basis of psoriasis.

    Nograles, Kristine E / Davidovici, Batya / Krueger, James G

    Seminars in cutaneous medicine and surgery

    2010  Volume 29, Issue 1, Page(s) 3–9

    Abstract: Psoriasis vulgaris is a multifactorial heritable disease characterized by severe inflammation resulting in poorly differentiated, hyperproliferative keratinocytes. Recent advances in genetic analyses have implicated components regulating the interleukin ( ...

    Abstract Psoriasis vulgaris is a multifactorial heritable disease characterized by severe inflammation resulting in poorly differentiated, hyperproliferative keratinocytes. Recent advances in genetic analyses have implicated components regulating the interleukin (IL)-23 and nuclear factor-kappaB pathways as risk factors for psoriasis. These inflammatory pathways exhibit increased activity in skin lesions, and promote secretion of various cytokines, such as IL-17 and IL-22. Unrestrained, the activated inflammatory cytokine network in psoriasis may trigger a vicious cycle of inflammation and cellular proliferation that ultimately results in lesion formation. These advances in genetic analyses, together with the progress made in targeted biological therapy, pave the path to tailor treatment on the basis of an individual's genetic and immunologic profile.
    MeSH term(s) CD4-Positive T-Lymphocytes/physiology ; Humans ; Interleukin-23/physiology ; Interleukins/physiology ; Lymphocyte Activation/physiology ; Psoriasis/genetics ; Psoriasis/immunology ; Psoriasis/pathology ; Interleukin-22
    Chemical Substances Interleukin-23 ; Interleukins
    Language English
    Publishing date 2010-04-29
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 1355511-x
    ISSN 1558-0768 ; 1085-5629
    ISSN (online) 1558-0768
    ISSN 1085-5629
    DOI 10.1016/j.sder.2010.03.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: New insights into the pathogenesis and genetics of psoriatic arthritis.

    Nograles, Kristine E / Brasington, Richard D / Bowcock, Anne M

    Nature clinical practice. Rheumatology

    2009  Volume 5, Issue 2, Page(s) 83–91

    Abstract: Psoriasis vulgaris and psoriatic arthritis (PsA) are inter-related heritable diseases. Psoriatic skin is characterized by hyperproliferative, poorly differentiated keratinocytes and severe inflammation. Psoriatic joints are characterized by highly ... ...

    Abstract Psoriasis vulgaris and psoriatic arthritis (PsA) are inter-related heritable diseases. Psoriatic skin is characterized by hyperproliferative, poorly differentiated keratinocytes and severe inflammation. Psoriatic joints are characterized by highly inflamed synovia and entheses with focal erosions of cartilage and bone. Genetic analyses have uncovered risk factors shared by both psoriasis and PsA. Predisposition to psoriasis and PsA arising from common variation is most strongly conferred by the HLA class I region. Other genetic risk factors implicate the interleukin (IL)-23 pathway and the induction and regulation of type 17 T-helper cells in the pathogenesis of both diseases. Secretion of cytokines, such as IL-22 and IL-17, could result in the hyperproliferative phenotype of keratinocytes and potentially synoviocytes, leading to a vicious cycle of cellular proliferation and inflammation in both the skin and joints. In synovial tissue, disease-related cytokines could also promote osteoclast formation, resulting in bone erosion. The next step will be to identify genetic risk factors specifically associated with PsA. Although therapies that target tumor necrosis factor are often highly successful in the treatment of both diseases, genetic findings are likely to lead to the development of treatments tailored to an individual's genetic profile.
    MeSH term(s) Arthritis, Psoriatic/etiology ; Arthritis, Psoriatic/genetics ; Genetic Predisposition to Disease ; Humans ; Interleukin-23/genetics ; Risk Factors ; T-Lymphocytes, Helper-Inducer/immunology
    Chemical Substances Interleukin-23
    Language English
    Publishing date 2009-01-11
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2228569-6
    ISSN 1745-8390 ; 1745-8382
    ISSN (online) 1745-8390
    ISSN 1745-8382
    DOI 10.1038/ncprheum0987
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Self-peptides prolong survival in murine autoimmunity via reduced IL-2/IL-7-mediated STAT5 signaling, CD8 coreceptor, and V alpha 2 down-regulation.

    Gutermuth, Jan / Nograles, Kristine E / Miyagawa, Fumi / Nelson, Emily / Cho, Young-Hun / Katz, Stephen I

    Journal of immunology (Baltimore, Md. : 1950)

    2009  Volume 183, Issue 5, Page(s) 3130–3138

    Abstract: Although the pathogenic role of B cells and CD4 T cells has been studied extensively, less is known about the role of CD8 T cells in autoimmunity and self-tolerance. To evaluate the role of CD8 T cells in autoimmunity and its modulation using self- ... ...

    Abstract Although the pathogenic role of B cells and CD4 T cells has been studied extensively, less is known about the role of CD8 T cells in autoimmunity and self-tolerance. To evaluate the role of CD8 T cells in autoimmunity and its modulation using self-peptides, we used mice expressing soluble OVA (sOVA) under control of the keratin-14 promoter. Spontaneous autoimmunity occurred when sOVA mice were crossed with OT-I mice, whose CD8 T cells carry a Valpha2/Vbeta5-transgenic TCR with specificity for the OVA(257-264) peptide. Eighty-three percent of OVA/OT-I mice died during the first 2 wk of life due to multiple organ inflammation. In contrast, preventive or therapeutic OVA(257-264) peptide injections induced a dose-dependent increase in survival. Healthy survivors exhibited reductions in peripheral CD8 T cells, CD8 coreceptor, and Valpha2 expression. Furthermore, CD8 T cells from healthy mice were anergic and could not be activated by exogenous IL-2. A block in IL-2/IL-7 signaling via the STAT5 pathway provided the basis for low surface expression of the CD8 coreceptor and failure of IL-2 to break CD8 T cell anergy. Thus, the soluble TCR ligand triggered multiple tolerance mechanisms in these sOVA/OT-I mice, making this treatment approach a potential paradigm for modulating human autoimmune diseases.
    MeSH term(s) Animals ; Autoimmune Diseases/immunology ; Autoimmune Diseases/mortality ; Autoimmune Diseases/therapy ; CD8 Antigens/metabolism ; Chickens ; Clonal Anergy/genetics ; Clonal Anergy/immunology ; Down-Regulation/genetics ; Down-Regulation/immunology ; Immune Tolerance/genetics ; Interleukin-2/antagonists & inhibitors ; Interleukin-2/physiology ; Interleukin-7/antagonists & inhibitors ; Interleukin-7/physiology ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Mice, Transgenic ; Ovalbumin/administration & dosage ; Ovalbumin/genetics ; Ovalbumin/immunology ; Ovalbumin/physiology ; Peptide Fragments/administration & dosage ; Peptide Fragments/genetics ; Peptide Fragments/immunology ; Peptide Fragments/physiology ; Receptors, Antigen, T-Cell/antagonists & inhibitors ; Receptors, Antigen, T-Cell/metabolism ; Receptors, Antigen, T-Cell, alpha-beta/antagonists & inhibitors ; Receptors, Antigen, T-Cell, alpha-beta/biosynthesis ; STAT5 Transcription Factor/antagonists & inhibitors ; STAT5 Transcription Factor/metabolism ; STAT5 Transcription Factor/physiology ; Signal Transduction/genetics ; Signal Transduction/immunology ; Solubility ; Survival Analysis
    Chemical Substances CD8 Antigens ; CD8 receptor ; Interleukin-2 ; Interleukin-7 ; OVA-8 ; Peptide Fragments ; Receptors, Antigen, T-Cell ; Receptors, Antigen, T-Cell, alpha-beta ; STAT5 Transcription Factor ; Ovalbumin (9006-59-1)
    Language English
    Publishing date 2009-08-12
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Intramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 3056-9
    ISSN 1550-6606 ; 0022-1767 ; 1048-3233 ; 1047-7381
    ISSN (online) 1550-6606
    ISSN 0022-1767 ; 1048-3233 ; 1047-7381
    DOI 10.4049/jimmunol.0900793
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top